2023
Systematic review and meta-analysis of safety and efficacy of atezolizumab/ bevacizumab in Child-Pugh class B patients with hepatocellular carcinoma
Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G, Torres M, Strazzabosco M, Giannini E. Systematic review and meta-analysis of safety and efficacy of atezolizumab/ bevacizumab in Child-Pugh class B patients with hepatocellular carcinoma. Digestive And Liver Disease 2023, 55: s221. DOI: 10.1016/j.dld.2023.08.025.Peer-Reviewed Original ResearchChild-Pugh class B patientsClass B patientsDisease control rateObjective response rateImpaired liver functionB patientsHepatocellular carcinomaLiver functionChild-Pugh B cirrhosisTreatment-related adverse eventsHigher objective response rateAdverse events gradeBest supportive careMedian overall survivalProgression-free survivalIndividualization of treatmentClass AB cirrhosisChild-PughCohort studyFree survivalOverall survivalSupportive careAdverse eventsOncological efficacy
2022
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis
Kayali S, Pasta A, Torres M, Jaffe A, Strazzabosco M, Marenco S, Giannini EG. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. Liver International 2022, 43: 8-17. PMID: 36102312, PMCID: PMC10087158, DOI: 10.1111/liv.15419.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsLiver transplant recipientsGraft rejectionOverall survivalICI therapyCheckpoint inhibitorsICI treatmentPooled analysisSystematic reviewDe novo malignanciesAcute graft rejectionDisease control rateRecurrent hepatocellular carcinomaShorter overall survivalGraft lossNovo malignanciesLiver transplantationLT recipientsTransplant recipientsAdvanced malignanciesProspective studyControl rateCase reportHepatocellular carcinomaPatients